HEADER TRANSFERASE 01-JUL-11 3ZT1 TITLE SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE TITLE 2 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN COMPND MOL_ID: 1; COMPND 2 MOLECULE: INTEGRASE; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: CORE CATALYTIC DOMAIN, RESIDUES 56-212; COMPND 5 EC: 2.7.7.-; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES; COMPND 8 OTHER_DETAILS: INHIBITOR BOUND TO LEDGF BINDING SITE SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS; SOURCE 3 ORGANISM_TAXID: 12721; SOURCE 4 STRAIN: TYPE 1; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_VECTOR: PET28 KEYWDS TRANSFERASE, AIDS EXPDTA X-RAY DIFFRACTION AUTHOR T.S.PEAT,J.NEWMAN,D.I.RHODES,N.VANDERGRAAFF,G.LE,E.D.JONES,J.A.SMITH, AUTHOR 2 J.A.V.COATES,N.THIENTHONG,O.DOLEZAL,J.H.RYAN,G.P.SAVAGE,C.L.FRANCIS, AUTHOR 3 J.J.DEADMAN REVDAT 3 20-DEC-23 3ZT1 1 REMARK REVDAT 2 01-AUG-12 3ZT1 1 AUTHOR JRNL REVDAT 1 11-JUL-12 3ZT1 0 JRNL AUTH T.S.PEAT,D.I.RHODES,N.VANDEGRAAFF,G.LE,J.A.SMITH,L.J.CLARK, JRNL AUTH 2 E.D.JONES,J.A.V.COATES,N.THIENTHONG,J.NEWMAN,O.DOLEZAL, JRNL AUTH 3 R.MULDER,J.H.RYAN,G.P.SAVAGE,C.L.FRANCIS,J.J.DEADMAN JRNL TITL SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HUMAN JRNL TITL 2 IMMUNODEFICIENCY VIRUS INTEGRASE IDENTIFIED BY FRAGMENT JRNL TITL 3 SCREENING AND STRUCTURE BASED DESIGN. JRNL REF PLOS ONE V. 7 40147 2012 JRNL REFN ESSN 1932-6203 JRNL PMID 22808106 JRNL DOI 10.1371/JOURNAL.PONE.0040147 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH D.I.RHODES,T.S.PEAT,N.VANDEGRAAFF,D.JEEVARAJAH,G.LE, REMARK 1 AUTH 2 E.D.JONES,J.A.SMITH,J.A.COATES,L.J.WINFIELD,N.THIENTHONG, REMARK 1 AUTH 3 J.NEWMAN,D.LUCENT,J.H.RYAN,G.P.SAVAGE,C.L.FRANCIS, REMARK 1 AUTH 4 J.J.DEADMAN REMARK 1 TITL STRUCTURAL BASIS FOR A NEW MECHANISM OF INHIBITION OF HIV-1 REMARK 1 TITL 2 INTEGRASE IDENTIFIED BY FRAGMENT SCREENING AND REMARK 1 TITL 3 STRUCTURE-BASED DESIGN. REMARK 1 REF ANTIVIR.CHEM.CHEMOTHER. V. 21 155 2011 REMARK 1 REFN ISSN 0956-3202 REMARK 1 PMID 21602613 REMARK 1 DOI 10.3851/IMP1716 REMARK 2 REMARK 2 RESOLUTION. 1.75 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.75 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 45.04 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 3 NUMBER OF REFLECTIONS : 35588 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.176 REMARK 3 R VALUE (WORKING SET) : 0.175 REMARK 3 FREE R VALUE : 0.199 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1899 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.75 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.80 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2655 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 100.0 REMARK 3 BIN R VALUE (WORKING SET) : 0.2910 REMARK 3 BIN FREE R VALUE SET COUNT : 154 REMARK 3 BIN FREE R VALUE : 0.3450 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2318 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 117 REMARK 3 SOLVENT ATOMS : 121 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 22.07 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 21.61 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.32000 REMARK 3 B22 (A**2) : 0.32000 REMARK 3 B33 (A**2) : -0.48000 REMARK 3 B12 (A**2) : 0.16000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.102 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.097 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.065 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 1.998 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.962 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.954 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2622 ; 0.013 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3591 ; 1.392 ; 1.980 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 342 ; 5.312 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 108 ;31.201 ;25.370 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 456 ;13.578 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 8 ;10.053 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 400 ; 0.091 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2034 ; 0.006 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 1224 ; 0.212 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 1778 ; 0.303 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 148 ; 0.135 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 60 ; 0.256 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 8 ; 0.054 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1614 ; 0.941 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2532 ; 1.442 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1191 ; 1.935 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1035 ; 2.819 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 3ZT1 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 01-JUL-11. REMARK 100 THE DEPOSITION ID IS D_1290048888. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 28-MAY-09 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : AUSTRALIAN SYNCHROTRON REMARK 200 BEAMLINE : MX1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.96 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210R REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 37523 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.750 REMARK 200 RESOLUTION RANGE LOW (A) : 66.670 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 5.600 REMARK 200 R MERGE (I) : 0.08000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 15.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.75 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.84 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 5.60 REMARK 200 R MERGE FOR SHELL (I) : 0.57000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.400 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 3NF7 REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 50.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.45 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: THE PROTEIN WAS CONCENTRATED TO 5.5 REMARK 280 MG/ML IN 4 0MM TRIS PH 8.0, 250 MM NACL, 30 MM MGCL2, 5 MM DTT REMARK 280 AND SET UP IN A 1:1 RATIO WITH 1.6 TO 2.0 M AMMONIUM SULFATE, REMARK 280 100 MM SODIUM ACETATE BUFFER PH 5.0 TO 5.5., PH 5.5 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 31 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 22.22433 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 44.44867 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5680 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 13560 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -116.2 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED RESIDUE IN CHAIN A, CYS 56 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN A, PHE 139 TO ASP REMARK 400 ENGINEERED RESIDUE IN CHAIN A, PHE 185 TO HIS REMARK 400 ENGINEERED RESIDUE IN CHAIN B, CYS 56 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN B, PHE 139 TO ASP REMARK 400 ENGINEERED RESIDUE IN CHAIN B, PHE 185 TO HIS REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 46 REMARK 465 GLY A 47 REMARK 465 SER A 48 REMARK 465 SER A 49 REMARK 465 HIS A 50 REMARK 465 HIS A 51 REMARK 465 HIS A 52 REMARK 465 HIS A 53 REMARK 465 HIS A 54 REMARK 465 HIS A 55 REMARK 465 SER A 56 REMARK 465 GLY A 189 REMARK 465 GLY A 190 REMARK 465 ILE A 191 REMARK 465 GLY A 192 REMARK 465 THR A 210 REMARK 465 LYS A 211 REMARK 465 GLU A 212 REMARK 465 MET B 46 REMARK 465 GLY B 47 REMARK 465 SER B 48 REMARK 465 SER B 49 REMARK 465 HIS B 50 REMARK 465 HIS B 51 REMARK 465 HIS B 52 REMARK 465 HIS B 53 REMARK 465 HIS B 54 REMARK 465 HIS B 55 REMARK 465 SER B 56 REMARK 465 GLY B 189 REMARK 465 GLY B 190 REMARK 465 ILE B 191 REMARK 465 GLY B 192 REMARK 465 THR B 210 REMARK 465 LYS B 211 REMARK 465 GLU B 212 REMARK 600 REMARK 600 HETEROGEN REMARK 600 REMARK 600 OM1 (4-CARBOXY-1,3-BENZODIOXOL-5-YL)METHYL-[[2- REMARK 600 [(4-METHOXYPHENYL)METHYLCARBAMOYL]PHENYL] REMARK 600 METHYL]AZANIUM IS AN ANALOGUE OF 3-BENZODIOXOLE- REMARK 600 4-CARBOXYLIC ACID. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1210 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1211 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1212 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1213 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 1214 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE OM1 A 1215 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 1210 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 1211 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 1212 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT B 1213 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO B 1214 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO B 1215 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE OM1 B 1216 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3ZSQ RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 3ZT2 RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 3ZT3 RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 3ZT4 RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 3ZSW RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 1HYZ RELATED DB: PDB REMARK 900 HIV INTEGRASE CORE DOMAIN COMPLEXED WITH A DERIVATIVE OFTETRAPHENYL REMARK 900 ARSONIUM. REMARK 900 RELATED ID: 3ZSO RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DESIGN REMARK 900 RELATED ID: 1HYV RELATED DB: PDB REMARK 900 HIV INTEGRASE CORE DOMAIN COMPLEXED WITH TETRAPHENYLARSONIUM REMARK 900 RELATED ID: 3ZSX RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 3ZSZ RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 3ZT0 RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 3ZSV RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 3ZSY RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN REMARK 900 RELATED ID: 3ZSR RELATED DB: PDB REMARK 900 SMALL MOLECULE INHIBITORS OF THE LEDGF SITE OF HIV TYPE 1 INTEGRASE REMARK 900 IDENTIFIED BY FRAGMENT SCREENING AND STRUCTURE BASED DRUG DESIGN DBREF 3ZT1 A 56 212 UNP Q76353 Q76353_9HIV1 56 212 DBREF 3ZT1 B 56 212 UNP Q76353 Q76353_9HIV1 56 212 SEQADV 3ZT1 MET A 46 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 GLY A 47 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 SER A 48 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 SER A 49 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS A 50 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS A 51 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS A 52 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS A 53 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS A 54 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS A 55 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 SER A 56 UNP Q76353 CYS 56 ENGINEERED MUTATION SEQADV 3ZT1 ASP A 139 UNP Q76353 PHE 139 ENGINEERED MUTATION SEQADV 3ZT1 HIS A 185 UNP Q76353 PHE 185 ENGINEERED MUTATION SEQADV 3ZT1 MET B 46 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 GLY B 47 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 SER B 48 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 SER B 49 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS B 50 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS B 51 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS B 52 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS B 53 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS B 54 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 HIS B 55 UNP Q76353 EXPRESSION TAG SEQADV 3ZT1 SER B 56 UNP Q76353 CYS 56 ENGINEERED MUTATION SEQADV 3ZT1 ASP B 139 UNP Q76353 PHE 139 ENGINEERED MUTATION SEQADV 3ZT1 HIS B 185 UNP Q76353 PHE 185 ENGINEERED MUTATION SEQRES 1 A 167 MET GLY SER SER HIS HIS HIS HIS HIS HIS SER SER PRO SEQRES 2 A 167 GLY ILE TRP GLN LEU ASP CYS THR HIS LEU GLU GLY LYS SEQRES 3 A 167 VAL ILE LEU VAL ALA VAL HIS VAL ALA SER GLY TYR ILE SEQRES 4 A 167 GLU ALA GLU VAL ILE PRO ALA GLU THR GLY GLN GLU THR SEQRES 5 A 167 ALA TYR PHE LEU LEU LYS LEU ALA GLY ARG TRP PRO VAL SEQRES 6 A 167 LYS THR VAL HIS THR ASP ASN GLY SER ASN PHE THR SER SEQRES 7 A 167 THR THR VAL LYS ALA ALA CYS TRP TRP ALA GLY ILE LYS SEQRES 8 A 167 GLN GLU ASP GLY ILE PRO TYR ASN PRO GLN SER GLN GLY SEQRES 9 A 167 VAL ILE GLU SER MET ASN LYS GLU LEU LYS LYS ILE ILE SEQRES 10 A 167 GLY GLN VAL ARG ASP GLN ALA GLU HIS LEU LYS THR ALA SEQRES 11 A 167 VAL GLN MET ALA VAL PHE ILE HIS ASN HIS LYS ARG LYS SEQRES 12 A 167 GLY GLY ILE GLY GLY TYR SER ALA GLY GLU ARG ILE VAL SEQRES 13 A 167 ASP ILE ILE ALA THR ASP ILE GLN THR LYS GLU SEQRES 1 B 167 MET GLY SER SER HIS HIS HIS HIS HIS HIS SER SER PRO SEQRES 2 B 167 GLY ILE TRP GLN LEU ASP CYS THR HIS LEU GLU GLY LYS SEQRES 3 B 167 VAL ILE LEU VAL ALA VAL HIS VAL ALA SER GLY TYR ILE SEQRES 4 B 167 GLU ALA GLU VAL ILE PRO ALA GLU THR GLY GLN GLU THR SEQRES 5 B 167 ALA TYR PHE LEU LEU LYS LEU ALA GLY ARG TRP PRO VAL SEQRES 6 B 167 LYS THR VAL HIS THR ASP ASN GLY SER ASN PHE THR SER SEQRES 7 B 167 THR THR VAL LYS ALA ALA CYS TRP TRP ALA GLY ILE LYS SEQRES 8 B 167 GLN GLU ASP GLY ILE PRO TYR ASN PRO GLN SER GLN GLY SEQRES 9 B 167 VAL ILE GLU SER MET ASN LYS GLU LEU LYS LYS ILE ILE SEQRES 10 B 167 GLY GLN VAL ARG ASP GLN ALA GLU HIS LEU LYS THR ALA SEQRES 11 B 167 VAL GLN MET ALA VAL PHE ILE HIS ASN HIS LYS ARG LYS SEQRES 12 B 167 GLY GLY ILE GLY GLY TYR SER ALA GLY GLU ARG ILE VAL SEQRES 13 B 167 ASP ILE ILE ALA THR ASP ILE GLN THR LYS GLU HET SO4 A1210 5 HET SO4 A1211 5 HET SO4 A1212 5 HET SO4 A1213 5 HET EDO A1214 4 HET OM1 A1215 33 HET SO4 B1210 5 HET SO4 B1211 5 HET SO4 B1212 5 HET ACT B1213 4 HET EDO B1214 4 HET EDO B1215 4 HET OM1 B1216 33 HETNAM SO4 SULFATE ION HETNAM EDO 1,2-ETHANEDIOL HETNAM OM1 (4-CARBOXY-1,3-BENZODIOXOL-5-YL)METHYL-[[2-[(4- HETNAM 2 OM1 METHOXYPHENYL)METHYLCARBAMOYL]PHENYL]METHYL]AZANIUM HETNAM ACT ACETATE ION HETSYN EDO ETHYLENE GLYCOL FORMUL 3 SO4 7(O4 S 2-) FORMUL 7 EDO 3(C2 H6 O2) FORMUL 8 OM1 2(C25 H25 N2 O6 1+) FORMUL 12 ACT C2 H3 O2 1- FORMUL 16 HOH *121(H2 O) HELIX 1 1 THR A 93 TRP A 108 1 16 HELIX 2 2 ASN A 117 SER A 123 1 7 HELIX 3 3 SER A 123 GLY A 134 1 12 HELIX 4 4 PRO A 145 ARG A 166 1 22 HELIX 5 5 ASP A 167 ALA A 169 5 3 HELIX 6 6 HIS A 171 LYS A 186 1 16 HELIX 7 7 SER A 195 GLN A 209 1 15 HELIX 8 8 THR B 93 TRP B 108 1 16 HELIX 9 9 ASN B 117 SER B 123 1 7 HELIX 10 10 SER B 123 ALA B 133 1 11 HELIX 11 11 PRO B 145 ARG B 166 1 22 HELIX 12 12 ASP B 167 ALA B 169 5 3 HELIX 13 13 HIS B 171 LYS B 186 1 16 HELIX 14 14 SER B 195 GLN B 209 1 15 SHEET 1 AA 5 ILE A 84 ILE A 89 0 SHEET 2 AA 5 LYS A 71 HIS A 78 -1 O VAL A 72 N ILE A 89 SHEET 3 AA 5 ILE A 60 LEU A 68 -1 O GLN A 62 N VAL A 77 SHEET 4 AA 5 THR A 112 HIS A 114 1 O THR A 112 N TRP A 61 SHEET 5 AA 5 LYS A 136 GLU A 138 1 O LYS A 136 N VAL A 113 SHEET 1 BA 5 ILE B 84 ILE B 89 0 SHEET 2 BA 5 LYS B 71 HIS B 78 -1 O VAL B 72 N ILE B 89 SHEET 3 BA 5 ILE B 60 LEU B 68 -1 O GLN B 62 N VAL B 77 SHEET 4 BA 5 THR B 112 HIS B 114 1 O THR B 112 N TRP B 61 SHEET 5 BA 5 LYS B 136 GLU B 138 1 O LYS B 136 N VAL B 113 SITE 1 AC1 5 THR A 66 HIS A 67 LYS A 111 LYS A 136 SITE 2 AC1 5 LYS A 159 SITE 1 AC2 6 LYS A 71 ARG A 166 HIS A 171 LEU A 172 SITE 2 AC2 6 HOH A2007 HOH A2054 SITE 1 AC3 7 GLU A 85 ALA A 86 GLU A 87 PHE A 100 SITE 2 AC3 7 LYS A 103 HOH A2015 ARG B 107 SITE 1 AC4 6 GLY A 94 SER A 123 THR A 124 THR A 125 SITE 2 AC4 6 EDO A1214 HOH A2042 SITE 1 AC5 5 THR A 93 GLY A 94 GLN A 95 SO4 A1213 SITE 2 AC5 5 HOH A2066 SITE 1 AC6 13 ASP A 167 GLN A 168 ALA A 169 GLU A 170 SITE 2 AC6 13 HIS A 171 THR A 174 MET A 178 HOH A2067 SITE 3 AC6 13 GLN B 95 ALA B 98 TYR B 99 ALA B 128 SITE 4 AC6 13 ALA B 129 SITE 1 AC7 5 THR B 66 HIS B 67 LYS B 111 LYS B 136 SITE 2 AC7 5 LYS B 159 SITE 1 AC8 6 LYS B 71 ARG B 166 HIS B 171 LEU B 172 SITE 2 AC8 6 HOH B2007 HOH B2042 SITE 1 AC9 6 SER B 123 THR B 124 THR B 125 EDO B1214 SITE 2 AC9 6 EDO B1215 HOH B2031 SITE 1 BC1 6 ARG A 107 HOH A2015 GLU B 85 GLU B 87 SITE 2 BC1 6 PHE B 100 LYS B 103 SITE 1 BC2 6 THR B 93 GLY B 94 GLN B 95 SO4 B1212 SITE 2 BC2 6 EDO B1215 HOH B2052 SITE 1 BC3 6 GLY B 94 SER B 119 ASN B 120 SO4 B1212 SITE 2 BC3 6 EDO B1214 HOH B2028 SITE 1 BC4 13 GLN A 95 ALA A 98 TYR A 99 ALA A 128 SITE 2 BC4 13 ALA A 129 HOH A2022 ASP B 167 GLN B 168 SITE 3 BC4 13 ALA B 169 GLU B 170 HIS B 171 THR B 174 SITE 4 BC4 13 MET B 178 CRYST1 70.586 70.586 66.673 90.00 90.00 120.00 P 31 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.014167 0.008179 0.000000 0.00000 SCALE2 0.000000 0.016359 0.000000 0.00000 SCALE3 0.000000 0.000000 0.014999 0.00000